Optinose Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapeutic solutions for patients suffering from sinus and allergy-related conditions
The company's primary product utilizes its proprietary drug delivery technology to administer medications directly to the nasal cavity, aimed at improving the treatment efficacy for various disorders, including chronic rhinosinusitis and allergic rhinitis. Through its commitment to research and development, Optinose strives to enhance patient outcomes and quality of life by delivering effective, non-invasive treatment options.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of OptiNose, Inc. (NasdaqGS: OPTN) to Paratek Pharmaceuticals. Under the terms of the proposed transaction, shareholders of OptiNose will receive $9.00 per share in cash, plus up to $5.00 per share in contingent value rights payable in the event that certain net revenue milestones are achieved by XHANCE. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
NEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BALA CYNWYD, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Paratek will acquire Optniose's outstanding shares for $9 apiece in cash, representing a 50% premium to the stock’s closing trading price of $6 on March 19.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Optinose, Inc. (NASDAQ: OPTN) to Paratek Pharmaceuticals is fair to Optinose shareholders. Under the terms of the proposed transaction, Paratek will acquire Optinose for $9.00 per share in cash, plus up to $5.00 per share in contingent value rights payable in the event that certain net revenue milestones are achieved by XHANCE.
The Ademi Firm is investigating Optinose (NASDAQ:OPTN) for possible breaches of fiduciary duty and other violations of law in its transaction with Paratek.
YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time.
YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Standard Time, on December 30, 2024. Beginning with the opening of trading on December 31, 2024, Optinose’s common stock will trade on the Nasdaq Global Select Market (“Nasdaq”) on a split-adjusted basis under a new CUSIP number 68404V209 and Optinose’s existing trading symbol “OPTN.”
YARDLEY, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 at 1:30 p.m. ET.
